MID-VOLUME · HOSP-HEAVY
cholestyramine Side Effects
cholestyramine (also sold as Questran) sits MID-VOLUME #301 of 524 by FAERS report count. Lead signal: HOSP-HEAVY - 33.7% mention hospitalization (3,888 reports). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 11,539
- FAERS reports
FDA Adverse Event Reporting System extract for cholestyramine. Stamp set WATCHLIST · DEATH-HEAVY · HOSP-HEAVY. How figures are compiled.
cholestyramine: 33.7% mention hospitalization (3,888 reports). Death stamp DEATH-HEAVY; volume band MID-VOLUME #301 of 524 by FAERS report count.
Mid-book FAERS page for cholestyramine (Questran) (11,539 reports). Signature HOSP-HEAVY. Dominant age band on file: 45-64. Educational reference only.
Counts from the openFDA FAERS extract (2004–2025). Stamps WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
DIARRHOEA leads 1,631 of 11,539 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (2,482 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (811 reports, 7.0%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 339 |
| DIARRHOEA | 87 |
| DYSPNOEA | 62 |
| ACUTE KIDNEY INJURY | 61 |
| SEPSIS | 55 |
| RENAL FAILURE | 51 |
| THROMBOCYTOPENIA | 48 |
| PNEUMONIA | 45 |
| ASTHENIA | 43 |
| CARDIAC ARREST | 37 |
| VOMITING | 37 |
| NAUSEA | 36 |
| WEIGHT DECREASED | 34 |
| CHRONIC KIDNEY DISEASE | 32 |
| FATIGUE | 31 |
| ANAEMIA | 30 |
| ABDOMINAL PAIN | 29 |
| PAIN | 29 |
| RESPIRATORY FAILURE | 29 |
Reactions in Hospitalization Reports
Hospitalization is HEAVY (3,888, 33.7% of the book). Top reactions in those rows:
| Reaction | Reports |
|---|---|
| DIARRHOEA | 597 |
| FATIGUE | 303 |
| NAUSEA | 290 |
| DYSPNOEA | 272 |
| VOMITING | 271 |
| ABDOMINAL PAIN | 257 |
| PNEUMONIA | 254 |
| WEIGHT DECREASED | 244 |
| ASTHENIA | 237 |
| DEHYDRATION | 234 |
| FALL | 216 |
| PYREXIA | 188 |
| ACUTE KIDNEY INJURY | 187 |
| PAIN | 187 |
| URINARY TRACT INFECTION | 183 |
| ARTHRALGIA | 178 |
| HEADACHE | 174 |
| MALAISE | 161 |
How to read cholestyramine FAERS figures (WATCHLIST · DEATH-HEAVY · HOSP-HEAVY)
FAERS holds 11,539 voluntary reports linked to cholestyramine (Questran), 2004-2025. Death is listed on 811 (7.0%). Hospitalization appears on 3,888 (33.7%). Top co-reported indication: Product Used For Unknown Indication.
Mid-volume extract - treat DEATH-HEAVY · HOSP-HEAVY as signal-detection rates next to 33.7% mention hospitalization (3,888 reports).
Read with cholestyramine
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-HEAVY stamps.
ABS(total_reports) peer at 11,690 FAERS cases (Δ 151 heavier vs cholestyramine); DEATH-MARKED · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 11,382 FAERS cases (Δ 157 lighter vs cholestyramine); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 11,380 FAERS cases (Δ 159 lighter vs cholestyramine); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 11,723 FAERS cases (Δ 184 heavier vs cholestyramine); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 55.1 pp vs cholestyramine's DEATH-HEAVY): CASELOAD · HOSP-MID.
cholestyramine stamps DEATH-HEAVY · HOSP-HEAVY; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload WATCHLIST and the label guide.